Applied DNA Partners with GenXys for Clinical Decision Support in PGx Testing

Applied DNA Sciences, Inc. (NASDAQ:APDN) has announced a partnership with GenXys Health Care Systems. This collaboration aims to enhance the use of Applied DNA's TR8™ pharmacogenomic (PGx) test by employing GenXys' clinical decision support software. The TR8 PGx test, approved by the New York State Department of Health, analyzes 120 genetic variants across 30 genes to identify drug-gene interactions, aiding in precision prescribing.

The partnership seeks to improve patient outcomes and reduce healthcare costs through data-driven approaches. Dr. James Hayward, CEO of Applied DNA, expressed confidence in the benefits of PGx-enabled precision prescribing. He highlighted the simplicity and long-term utility of the test, which can guide prescription decisions over a patient's lifetime.

GenXys' software will process genetic data from the TR8 PGx test, providing healthcare providers with actionable insights. Previous studies have shown that PGx-guided prescribing can enhance therapeutic efficacy, improve patient compliance, and reduce adverse reactions and rehospitalizations. The TR8 PGx test and testing service are performed in ADCL's certified laboratory.